Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a

Identifieur interne : 002F32 ( Main/Exploration ); précédent : 002F31; suivant : 002F33

Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a

Auteurs : Shunsuke Kohyama [Japon] ; Satoshi Ohno [Japon] ; Tatsuya Suda [Japon] ; Maiko Taneichi [Japon] ; Shoichi Yokoyama [Japon] ; Masahito Mori [Japon] ; Akiharu Kobavashi [Japon] ; Hidenori Havashi [Japon] ; Tetsuva Uchida [Japon] ; Masanori Matsui [Japon]

Source :

RBID : Pascal:09-0466845

Descripteurs français

English descriptors

Abstract

Spike and nucleocapsid are structural proteins of severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) and major targets for cytotoxic T lymphocytes (CTLs). In contrast, non-structural proteins encoded by two-thirds of viral genome are poorly characterized for cell-mediated immunity. We previously demonstrated that nucleocapsid-derived peptides chemically coupled to the surface of liposomes effectively elicited SARS-CoV-specific CTLs in mice. Here, we attempted to identify HLA-A*0201-restricted CTL epitopes derived from a non-structural polyprotein 1a (ppla) of SARS-CoV, and investigated whether liposomal peptides derived from pp1a were effective for CTL induction. Out of 30 peptides predicted on computational algorithms, nine peptides could significantly induce interferon gamma (IFN-γ)-producing CD8+ T cells in mice. These peptides were coupled to the surface of liposomes, and inoculated into mice. Six liposomal peptides effectively induced IFN-γ-producing CD8+ T cells and seven liposomal peptides including the six peptides primed CTLs showing in vivo killing activities. Further, CTLs induced by the seven liposomal peptides lysed an HLA-A*0201 positive cell line expressing naturally processed, ppla-derived peptides. Of note, one of the liposomal peptides induced high numbers of long-lasting memory CTLs. These data suggest that surface-linked liposomal peptides derived from ppla might offer an efficient CTL-based vaccine against SARS.


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a</title>
<author>
<name sortKey="Kohyama, Shunsuke" sort="Kohyama, Shunsuke" uniqKey="Kohyama S" first="Shunsuke" last="Kohyama">Shunsuke Kohyama</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Iruma-gun, Saitama 350-0495</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University</s1>
<s2>Sakado-city, Saitama 350-0295</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Sakado-city, Saitama 350-0295</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ohno, Satoshi" sort="Ohno, Satoshi" uniqKey="Ohno S" first="Satoshi" last="Ohno">Satoshi Ohno</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Iruma-gun, Saitama 350-0495</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University</s1>
<s2>Sakado-city, Saitama 350-0295</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Sakado-city, Saitama 350-0295</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Suda, Tatsuya" sort="Suda, Tatsuya" uniqKey="Suda T" first="Tatsuya" last="Suda">Tatsuya Suda</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Iruma-gun, Saitama 350-0495</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Taneichi, Maiko" sort="Taneichi, Maiko" uniqKey="Taneichi M" first="Maiko" last="Taneichi">Maiko Taneichi</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases</s1>
<s2>Musashimurayama-city, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName>
<settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Yokoyama, Shoichi" sort="Yokoyama, Shoichi" uniqKey="Yokoyama S" first="Shoichi" last="Yokoyama">Shoichi Yokoyama</name>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Drug Delivery System Development Division, Nippon Oil and Fat Corporation</s1>
<s2>Tokyo 150-6019</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName>
<settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Mori, Masahito" sort="Mori, Masahito" uniqKey="Mori M" first="Masahito" last="Mori">Masahito Mori</name>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Drug Delivery System Development Division, Nippon Oil and Fat Corporation</s1>
<s2>Tokyo 150-6019</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName>
<settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kobavashi, Akiharu" sort="Kobavashi, Akiharu" uniqKey="Kobavashi A" first="Akiharu" last="Kobavashi">Akiharu Kobavashi</name>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Drug Delivery System Development Division, Nippon Oil and Fat Corporation</s1>
<s2>Tokyo 150-6019</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName>
<settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Havashi, Hidenori" sort="Havashi, Hidenori" uniqKey="Havashi H" first="Hidenori" last="Havashi">Hidenori Havashi</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University</s1>
<s2>Sakado-city, Saitama 350-0295</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Sakado-city, Saitama 350-0295</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Uchida, Tetsuva" sort="Uchida, Tetsuva" uniqKey="Uchida T" first="Tetsuva" last="Uchida">Tetsuva Uchida</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases</s1>
<s2>Musashimurayama-city, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName>
<settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Matsui, Masanori" sort="Matsui, Masanori" uniqKey="Matsui M" first="Masanori" last="Matsui">Masanori Matsui</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Iruma-gun, Saitama 350-0495</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">09-0466845</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0466845 INIST</idno>
<idno type="RBID">Pascal:09-0466845</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000176</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000812</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000213</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000213</idno>
<idno type="wicri:doubleKey">0166-3542:2009:Kohyama S:efficient:induction:of</idno>
<idno type="wicri:Area/Main/Merge">002F90</idno>
<idno type="wicri:Area/Main/Curation">002F32</idno>
<idno type="wicri:Area/Main/Exploration">002F32</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a</title>
<author>
<name sortKey="Kohyama, Shunsuke" sort="Kohyama, Shunsuke" uniqKey="Kohyama S" first="Shunsuke" last="Kohyama">Shunsuke Kohyama</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Iruma-gun, Saitama 350-0495</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University</s1>
<s2>Sakado-city, Saitama 350-0295</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Sakado-city, Saitama 350-0295</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ohno, Satoshi" sort="Ohno, Satoshi" uniqKey="Ohno S" first="Satoshi" last="Ohno">Satoshi Ohno</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Iruma-gun, Saitama 350-0495</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University</s1>
<s2>Sakado-city, Saitama 350-0295</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Sakado-city, Saitama 350-0295</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Suda, Tatsuya" sort="Suda, Tatsuya" uniqKey="Suda T" first="Tatsuya" last="Suda">Tatsuya Suda</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Iruma-gun, Saitama 350-0495</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Taneichi, Maiko" sort="Taneichi, Maiko" uniqKey="Taneichi M" first="Maiko" last="Taneichi">Maiko Taneichi</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases</s1>
<s2>Musashimurayama-city, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName>
<settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Yokoyama, Shoichi" sort="Yokoyama, Shoichi" uniqKey="Yokoyama S" first="Shoichi" last="Yokoyama">Shoichi Yokoyama</name>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Drug Delivery System Development Division, Nippon Oil and Fat Corporation</s1>
<s2>Tokyo 150-6019</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName>
<settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Mori, Masahito" sort="Mori, Masahito" uniqKey="Mori M" first="Masahito" last="Mori">Masahito Mori</name>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Drug Delivery System Development Division, Nippon Oil and Fat Corporation</s1>
<s2>Tokyo 150-6019</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName>
<settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Kobavashi, Akiharu" sort="Kobavashi, Akiharu" uniqKey="Kobavashi A" first="Akiharu" last="Kobavashi">Akiharu Kobavashi</name>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Drug Delivery System Development Division, Nippon Oil and Fat Corporation</s1>
<s2>Tokyo 150-6019</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName>
<settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Havashi, Hidenori" sort="Havashi, Hidenori" uniqKey="Havashi H" first="Hidenori" last="Havashi">Hidenori Havashi</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Pathological Biochemistry, Faculty of Pharmaceutical Sciences, Josai University</s1>
<s2>Sakado-city, Saitama 350-0295</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Sakado-city, Saitama 350-0295</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Uchida, Tetsuva" sort="Uchida, Tetsuva" uniqKey="Uchida T" first="Tetsuva" last="Uchida">Tetsuva Uchida</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases</s1>
<s2>Musashimurayama-city, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName>
<settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Matsui, Masanori" sort="Matsui, Masanori" uniqKey="Matsui M" first="Masanori" last="Matsui">Masanori Matsui</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho</s1>
<s2>Iruma-gun, Saitama 350-0495</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<wicri:noRegion>Iruma-gun, Saitama 350-0495</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint>
<date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Cellular immunity</term>
<term>Conjugated compound</term>
<term>Cytotoxic T lymphocyte</term>
<term>Immunization</term>
<term>Immunoprophylaxis</term>
<term>Induction</term>
<term>Liposome</term>
<term>Polyprotein</term>
<term>Prevention</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Vaccination</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Induction</term>
<term>Lymphocyte T cytotoxique</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Immunisation</term>
<term>Vaccin</term>
<term>Vaccination</term>
<term>Liposome</term>
<term>Polyprotéine</term>
<term>Prévention</term>
<term>Immunoprophylaxie</term>
<term>Immunité cellulaire</term>
<term>Composé conjugué</term>
<term>Protéine non structurale</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Vaccin</term>
<term>Vaccination</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Spike and nucleocapsid are structural proteins of severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) and major targets for cytotoxic T lymphocytes (CTLs). In contrast, non-structural proteins encoded by two-thirds of viral genome are poorly characterized for cell-mediated immunity. We previously demonstrated that nucleocapsid-derived peptides chemically coupled to the surface of liposomes effectively elicited SARS-CoV-specific CTLs in mice. Here, we attempted to identify HLA-A
<sup>*</sup>
0201-restricted CTL epitopes derived from a non-structural polyprotein 1a (ppla) of SARS-CoV, and investigated whether liposomal peptides derived from pp1a were effective for CTL induction. Out of 30 peptides predicted on computational algorithms, nine peptides could significantly induce interferon gamma (IFN-γ)-producing CD8
<sup>+</sup>
T cells in mice. These peptides were coupled to the surface of liposomes, and inoculated into mice. Six liposomal peptides effectively induced IFN-γ-producing CD8
<sup>+</sup>
T cells and seven liposomal peptides including the six peptides primed CTLs showing in vivo killing activities. Further, CTLs induced by the seven liposomal peptides lysed an HLA-A
<sup>*</sup>
0201 positive cell line expressing naturally processed, ppla-derived peptides. Of note, one of the liposomal peptides induced high numbers of long-lasting memory CTLs. These data suggest that surface-linked liposomal peptides derived from ppla might offer an efficient CTL-based vaccine against SARS.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Japon</li>
</country>
<region>
<li>Région de Kantō</li>
</region>
<settlement>
<li>Tokyo</li>
</settlement>
</list>
<tree>
<country name="Japon">
<noRegion>
<name sortKey="Kohyama, Shunsuke" sort="Kohyama, Shunsuke" uniqKey="Kohyama S" first="Shunsuke" last="Kohyama">Shunsuke Kohyama</name>
</noRegion>
<name sortKey="Havashi, Hidenori" sort="Havashi, Hidenori" uniqKey="Havashi H" first="Hidenori" last="Havashi">Hidenori Havashi</name>
<name sortKey="Kobavashi, Akiharu" sort="Kobavashi, Akiharu" uniqKey="Kobavashi A" first="Akiharu" last="Kobavashi">Akiharu Kobavashi</name>
<name sortKey="Kohyama, Shunsuke" sort="Kohyama, Shunsuke" uniqKey="Kohyama S" first="Shunsuke" last="Kohyama">Shunsuke Kohyama</name>
<name sortKey="Matsui, Masanori" sort="Matsui, Masanori" uniqKey="Matsui M" first="Masanori" last="Matsui">Masanori Matsui</name>
<name sortKey="Mori, Masahito" sort="Mori, Masahito" uniqKey="Mori M" first="Masahito" last="Mori">Masahito Mori</name>
<name sortKey="Ohno, Satoshi" sort="Ohno, Satoshi" uniqKey="Ohno S" first="Satoshi" last="Ohno">Satoshi Ohno</name>
<name sortKey="Ohno, Satoshi" sort="Ohno, Satoshi" uniqKey="Ohno S" first="Satoshi" last="Ohno">Satoshi Ohno</name>
<name sortKey="Suda, Tatsuya" sort="Suda, Tatsuya" uniqKey="Suda T" first="Tatsuya" last="Suda">Tatsuya Suda</name>
<name sortKey="Taneichi, Maiko" sort="Taneichi, Maiko" uniqKey="Taneichi M" first="Maiko" last="Taneichi">Maiko Taneichi</name>
<name sortKey="Uchida, Tetsuva" sort="Uchida, Tetsuva" uniqKey="Uchida T" first="Tetsuva" last="Uchida">Tetsuva Uchida</name>
<name sortKey="Yokoyama, Shoichi" sort="Yokoyama, Shoichi" uniqKey="Yokoyama S" first="Shoichi" last="Yokoyama">Shoichi Yokoyama</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F32 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F32 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:09-0466845
   |texte=   Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021